Clinical Trials (PDQ®) - National Cancer Institute

Page Options

	Quick Links


	Director's Corner Dictionary of Cancer Terms NCI Drug Dictionary Funding Opportunities NCI Publications Advisory Boards and Groups Science Serving People Español

Questions about cancer?


	1-800-4-CANCER

	LiveHelp online chat

	NCI Highlights


	Maintenance Rituximab for Follicular Lymphoma Azacitidine Improves Survival in MDS Second Stem Cell Transplant Not Helpful in Myeloma

Phase II-Pilot Chemotherapy with Anguidine for Acute Nonlymphocytic Leukemia Refractory to Standard Therapy

Basic Trial Information
Objectives
Entry Criteria
Expected Enrollment
Outline
Trial Contact Information

Basic Trial Information

Phase Type Status Age Sponsor Protocol IDs
Phase II Treatment Closed over 21 NCI SWOG-8063

Objectives

I.  Determine the efficacy of anguidine for inducing a response in adults with 
acute nonlymphocytic leukemia refractory to standard forms of therapy.
II.  Assess the toxicity of this agent.

Entry Criteria

Disease Characteristics:

See General Eligibility Criteria

Patient Characteristics:

See General Eligibility Criteria

General Eligibility Criteria:

Adult patients with acute 
nonlymphocytic leukemia resistant to standard therapies who are not eligible 
for a higher priority protocol.  Patients must be over 21 years of age and 
have an M-3 marrow and a life expectancy of at least 4 weeks.  Patients should 
have recovered from prior significant drug toxicity.  Liver and kidney 
function must be adequate.

Expected Enrollment

45 patients will be entered.  Protocol closed April 1981.

Outline

Nonrandomized study.
Regimen A:  Induction.  Single-agent Chemotherapy.  Anguidine, ANG, NSC-141537.
Regimen B:  Maintenance.  Single-agent Chemotherapy.  ANG.

Trial Contact Information

Trial Lead Organizations

Southwest Oncology Group

Charles Coltman, MD, Protocol chair(Contact information may not be current)
Ph: 210-567-2710

Note: The purpose of most clinical trials listed in this database is to test new cancer treatments, or new methods of diagnosing, screening, or preventing cancer. Because all potentially harmful side effects are not known before a trial is conducted, dose and schedule modifications may be required for participants if they develop side effects from the treatment or test. The therapy or test described in this clinical trial is intended for use by clinical oncologists in carefully structured settings, and may not prove to be more effective than standard treatment. A responsible investigator associated with this clinical trial should be consulted before using this protocol.